← All indications
Myelodysplastic Syndromes
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Subtype terms (4)
More specific conditions that are subtypes of Myelodysplastic Syndromes in the MeSH hierarchy.
- Anemia, Refractory
62 drugs (36 approved, 26 experimental)
- Anemia, Sideroblastic
- GATA2 Deficiency
13 drugs (8 approved, 5 experimental)
- Hemoglobinuria, Paroxysmal
55 drugs (30 approved, 25 experimental)
Drugs by status
Approved for this indication (7)
Phase 4 trials (21)
- autologous hematopoietic stem cells
- darbepoetin beta
- posaconazole
- busulfan
- fludarabine
- tigecycline
- cyclosporine
- micafungin
- allogeneic bone marrow
- allogeneic hematopoietic stem cells
- cytarabine
- inactivated influenza vaccine
- vitamin d3
- Anti-thymocyte Globulin (Rabbit)
- cyclophosphamide
- idarubicin
- roxadustat
- cda-2
- sargramostim
- thiotepa
- epoetin
Phase 3 trials (111)
- autologous bone marrow derived mesenchymal cells
- enasidenib
- efprezimod alfa
- amitriptyline
- stem cells
- gemtuzumab ozogamicin
- moxifloxacin
- atir101
- alemtuzumab
- allogeneic stem cells
- rivogenlecleucel
- urea
- nystatin
- methotrexate
- sorafenib
- baricitinib
- multivitamins
- nicotinamide
- autologous cd34+ cells
- dalteparin
- cd45-depleted allogenic peripheral blood stem cell
- mycophenolate
- muromonab cd3
- caspofungin
- daunorubicin
- nivolumab
- cladribine
- quizartinib
- treosulfan
- ketamine
- +81 more
Phase 2 trials (330)
- Tomaralimab
- beclomethasone
- mercaptopurine
- doxercalciferol
- voriconazole
- interferon alpha-2b
- bp1001
- max-40279
- tp-0184
- rv-nyeso tcr pbmc
- ht-6184
- igf-methotrexate
- cis-retinoic acid
- siplizumab
- wt1 peptide-pulsed dendritic cells
- diphenhydramine
- pracinostat
- bendamustine
- hs-20106
- as01
- prednisone
- itacitinib
- car.70/il15-transduced cb-nk cells
- sel120
- trametinib
- ak117
- tamibarotene
- ixazomib
- chidamide
- cytokine induced killer cells
- +300 more
Phase 1 trials (261)
- ilorasertib
- bh-30236
- tetanus-cmv fusion peptide vaccine
- cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr
- icp-248
- multitaa t cells
- rem-422
- cc-95251
- vactosertib
- nis793
- a27.15
- becatecarin
- talazoparib
- co-argi-peg
- xk469
- s64315
- 7-hydroxystaurosporine
- dec-205/ny-eso-1 fusion protein cdx-1401
- Vorasidenib
- tqb2618
- cbx-250
- bpx-701
- prt1419
- gti-2040
- t-allo10
- onvansertib
- triapine
- autologous tumor cells
- vip943
- il-7
- +231 more
Other trials (20)
Organizations
Organization Involved with Phase 4 Indications (23)
- Hebrew University
- Roche
- Katholieke Universiteit Leuven
- Universidad Autonoma de Barcelona
- Astellas
- PETHEMA Foundation
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Grenoble Alps University
- University of London
- University of Maryland
- University of South Florida
- University of Valencia
- Soochow University
- Radboud University
- Association pour la recherche sur les Affections Malignes en Immunologie Sanguine
- Cornell University
- Chinese Society of Hematology
- Ben Gurion University
- Tianjin Medical University
- Harbin Medical University
- Eisai
- University of Arizona
- Tel Aviv University
Organization Involved with Phase 3 Indications (138)
- Medac
- Rutgers University
- Fondazione Italiana Diabete Onlus
- Cancer Research UK
- Astex Pharmaceuticals, Inc.
- Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)
- Onconova Therapeutics, Inc.
- University of Montreal
- New York Blood Center
- Johns Hopkins University
- Erasmus University Rotterdam
- Jiao Tong University
- Groupe Francophone des Myelodysplasies
- The Leukemia and Lymphoma Society
- Harvard University
- Eli Lilly
- University of Freiburg
- Merck
- Ohio State University
- ASO SS Antonio e Biagio e C Arrigo Alessandria, Italy
- Vanderbilt University
- University of Pittsburgh
- University of Liege
- European Organisation for Research and Treatment of Cancer
- Centre Henri Becquerel
- OncoImmune, Inc.
- Wayne State University
- HOVON - Dutch Haemato-Oncology Association
- The Christie NHS Foundation Trust
- University of Barcelona
- +108 more
Organization Involved with Phase 2 Indications (288)
- Assisi Foundation
- ZNA Antwerpen
- The Korean Society of Blood and Marrow Transplantation
- BioMAS Ltd
- Universita' Cattolica del Sacro Cuore
- Sclnow Biotechnology Co., Ltd.
- Ciusss de L'Est de l'Île de Montréal
- AnorMED
- University of California, San Francisco
- Boehringer Ingelheim
- Chu De Liège
- Sutter Health
- The Vaccine Company
- University of Paris
- MDS Consortium
- Food and Drug Administration
- Inner Mongolia International Mongolian Hospital
- Medical University of South Carolina
- Ozmosis Research Inc.
- Aarhus University
- OncoTherapy Science, Inc.
- Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon
- Department of Health and Human Services
- Van Andel Research Institute
- Hoag Memorial Hospital Presbyterian
- Kyowa Hakko Kirin
- Ewha Womans University
- BioLineRx, Ltd.
- Parexel
- University of Wisconsin
- +258 more
Organization Involved with Phase 1 Indications (95)
- Nkarta Inc.
- CASI Pharmaceuticals, Inc.
- PharmaMar
- Intrexon
- Boston Biomedical
- American Society for Blood and Marrow Transplantation
- Atara Biotherapeutics
- HonorHealth Research Institute
- Cato Research
- Plexxikon
- Innovive Pharmaceuticals
- Jasper Therapeutics, Inc.
- Telesta Therapeutics
- Prelude Therapeutics
- California Cancer Associates
- Epizyme, Inc.
- University of California, Berkeley
- Daiichi Sankyo
- University of Oxford
- Vasgene Therapeutics, Inc
- Loxo Oncology
- Selvita S.A.
- L K Whittier Foundation
- In8Bio
- Dartmouth University
- Threshold Pharmaceuticals
- Curis
- Imago BioSciences
- Big Ten Cancer Research Consortium
- The Alfred Hospital
- +65 more
Organization Involved with Other Experimental Indications (14)
- Fujian Medical University
- Gateway for Cancer Research
- Central South University
- Cellworks Group Inc.
- West Virginia University
- Integrated Community Oncology Network
- Hacettepe University
- National Institute on Aging (NIA)
- Nanjing Medical University
- Huazhong University of Science and Technology
- Aix-University of Marseille
- Guangzhou Medical University
- Upstate Carolina
- Shantou University